MCID: CHL066
MIFTS: 52

Cholangitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Cholangitis

MalaCards integrated aliases for Cholangitis:

Name: Cholangitis 12 29 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9446
ICD10 33 K83.0
ICD9CM 35 576.1
MeSH 44 D002761
NCIt 50 C26718
UMLS 73 C0008311

Summaries for Cholangitis

Disease Ontology : 12 A bile duct disease that is an inflammation of the bile duct.

MalaCards based summary : Cholangitis is related to sclerosing cholangitis, neonatal and suppurative cholangitis. An important gene associated with Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Influenza A and HTLV-I infection. The drugs Ciprofloxacin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and colon, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Related Diseases for Cholangitis

Diseases in the Cholangitis family:

Acute Cholangitis Chronic Cholangitis

Diseases related to Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 457)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 34.7 CLDN1 DCDC2
2 suppurative cholangitis 33.0 ABCB4 CRP DLAT TNF
3 cholelithiasis 32.6 ABCB4 ALB GPT
4 cholangitis, primary sclerosing 32.4 ABCB4 CFTR DLAT FUT2 GGT1 GPBAR1
5 cholecystitis 32.3 ABCB4 ALB F2 GPT
6 hepatitis 30.9 CLDN1 F2 GGT1 GPT TNF
7 autoimmune pancreatitis 30.9 CA2 CFTR HLA-DRB1 TNF
8 choledocholithiasis 30.7 ABCB4 ALB F2 GPT
9 pure red-cell aplasia 30.5 ALB HLA-B HLA-DRB1
10 alveolar echinococcosis 30.4 HLA-B HLA-DRB1 TNF
11 cholestasis 30.4 ABCB4 F2 GGT1 GPT
12 sclerosing cholangitis 30.3 ABCB4 ALB CD40LG CFTR CLDN1 DCDC2
13 primary biliary cirrhosis 30.1 ABCB4 ALB CD40LG DLAT F2 GGT1
14 liver cirrhosis 30.1 ALB F2 GGT1 GPT
15 hepatitis c 30.1 CLDN1 GGT1 GPT TNF
16 portal hypertension 30.1 ALB F2 GPT TNF
17 angioimmunoblastic lymphadenopathy with dysproteinemia 30.1 IL6 TNF
18 intrahepatic cholestasis 29.7 ABCB4 ALB GGT1 GPBAR1
19 fatty liver disease 29.6 GGT1 GPT IL6 TNF
20 hepatitis b 29.6 ALB F2 GGT1 GPT TNF
21 inflammatory bowel disease 29.5 ALB CRP HLA-B HLA-DRB1 IL6 TNF
22 biliary tract disease 29.4 ABCB4 ALB F2 GGT1 GPBAR1
23 acute pyelonephritis 29.4 ALB CRP IL6
24 cystitis 29.4 CRP IL6 TNF
25 liver disease 29.3 ABCB4 ALB DLAT F2 GGT1 GPT
26 autoimmune hepatitis 29.3 CD40LG DLAT F2 GGT1 GPT HLA-DRB1
27 bile duct disease 29.2 ABCB4 ALB F2 GGT1 GPBAR1 GPT
28 psoriatic arthritis 29.0 CRP HLA-B HLA-DRB1 IL6 TNF
29 acalculous cholecystitis 29.0 CD40LG CRP
30 obstructive jaundice 29.0 ALB F2 GGT1 GPBAR1 GPT IL6
31 pyelonephritis 28.9 ALB CRP IL6 TNF
32 bacterial meningitis 28.9 ALB CRP IL6 TNF
33 kawasaki disease 28.9 ALB CRP IL6 TNF
34 gastroenteritis 28.9 ALB CRP FUT2 IL6 TNF
35 sickle cell anemia 28.8 CD40LG F2 TNF
36 granulomatous hepatitis 28.8 CD40LG CRP GGT1
37 bronchiolitis 28.7 CD40LG IL6 TNF
38 autoimmune disease 28.7 CD40LG HLA-B HLA-DRB1 IL6 TNF
39 peritonitis 28.6 ALB CRP F2 IL6 TNF
40 hepatitis a 28.5 ALB CD40LG F2 GPT TNF
41 acquired immunodeficiency syndrome 28.5 ALB CD40LG HLA-B IL6 TNF
42 intussusception 28.5 CD40LG CFTR CRP IL6
43 echinococcosis 28.3 CD40LG HLA-B HLA-DRB1 IL6 TNF
44 diabetes mellitus 28.1 ALB CRP HLA-B HLA-DRB1 IL6 TNF
45 pneumonia 28.0 CD40LG CRP IL6 TNF
46 osteoporosis 27.8 ALB CA2 CRP IL6 TNF
47 myeloma, multiple 27.7 ALB CD40LG CRP IL6 TNF
48 meningitis 27.5 ALB CD40LG CRP IL6 TNF
49 leptospirosis 27.3 CD40LG CRP F2 IL6 TNF
50 rheumatoid arthritis 27.1 CD40LG CRP HLA-B HLA-DRB1 IL6 TNF

Comorbidity relations with Cholangitis via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Acute Pancreatitis
Biliary Tract Neoplasm Cholecystitis
Cholestasis Deficiency Anemia
Familial Atrial Fibrillation Gallbladder Cancer
Heart Disease Hepatitis
Intrahepatic Gall Duct Cancer Pancreatic Cancer
Pancreatitis, Hereditary Paralytic Ileus
Postcholecystectomy Syndrome Primary Biliary Cirrhosis
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Cholangitis:



Diseases related to Cholangitis

Symptoms & Phenotypes for Cholangitis

MGI Mouse Phenotypes related to Cholangitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.93 CRP F2 ABCB4 GGT1 ALB GPBAR1
2 digestive/alimentary MP:0005381 9.92 F2 ABCB4 FUT2 ALB CA2 IL6
3 endocrine/exocrine gland MP:0005379 9.91 ABCB4 GGT1 ALB GPBAR1 CA2 IL6
4 immune system MP:0005387 9.7 CRP F2 ABCB4 FUT2 GGT1 GPBAR1
5 reproductive system MP:0005389 9.28 F2 ABCB4 FUT2 GGT1 CA2 IL6

Drugs & Therapeutics for Cholangitis

Drugs for Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Cefoxitin Approved Phase 4,Not Applicable 35607-66-0 441199
4
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Vancomycin Approved Phase 4,Phase 3,Phase 1,Not Applicable 1404-90-6 441141 14969
7
Cefotaxime Approved Phase 4,Not Applicable 63527-52-6 456256 5742673
8
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
9
Racepinephrine Approved Phase 4 329-65-7 838
10
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
11
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 128-13-2 31401
12
Metronidazole Approved Phase 4,Phase 1,Not Applicable 443-48-1 4173
13
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
14
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
15
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
16
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
17
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
18
Prednisone Approved, Vet_approved Phase 4,Not Applicable 53-03-2 5865
19
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
20 Temocillin Approved, Investigational Phase 4 66148-78-5
21
Ofloxacin Approved Phase 4 82419-36-1 4583
22
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
23
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
24 Clavulanic Acid Phase 4
25 Respiratory System Agents Phase 4,Phase 1
26 Adrenergic Agents Phase 4
27 Adrenergic Agonists Phase 4
28 Adrenergic alpha-Agonists Phase 4
29 Adrenergic beta-Agonists Phase 4
30 Mydriatics Phase 4
31 Amoxicillin-Potassium Clavulanate Combination Phase 4
32 Neurotransmitter Agents Phase 4,Phase 2
33 Hormone Antagonists Phase 4,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 1,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Not Applicable
36 Vasoconstrictor Agents Phase 4,Phase 2
37 Anti-Asthmatic Agents Phase 4,Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
39 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Epinephryl borate Phase 4
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Not Applicable
45 Antitubercular Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Autonomic Agents Phase 4,Phase 1
47 Bronchodilator Agents Phase 4,Phase 1
48 Prednisolone acetate Phase 4,Not Applicable
49 glucocorticoids Phase 4,Phase 1
50 Methylprednisolone acetate Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 241)
# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis Unknown status NCT02057679 Phase 4 Amoxicillin clavulanic;Placebo
3 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
4 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
5 Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Unknown status NCT02839356 Phase 4 epinephrine;normal saline
6 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
7 Balloon Catheter vs. Basket Catheter for Endoscopic Bile Duct Stone Extraction Completed NCT02909595 Phase 4
8 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
9 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
10 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
11 A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients. Completed NCT00545402 Phase 4 Mycophenolate mofetil, adjusted dose;Tacrolimus;Corticosteroids, IV;Mycophenolate mofetil, Standard dose;Corticosteroids, PO
12 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
13 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
14 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
15 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
16 Temocillin Pharmacokinetics in Paediatrics Recruiting NCT02260102 Phase 4 Temocillin
17 Leflunomide for Maintenance of Remission in IgG4 Related Disease Recruiting NCT02703194 Phase 4 Prednisone;Leflunomide
18 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4 Vancomycin
19 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
20 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
21 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
22 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
23 Effect of Saline Irrigation to DEcrease Rate Of Residual Common Bile Duct Stones Unknown status NCT01425177 Phase 3
24 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
25 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
26 Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients Completed NCT00622869 Phase 3 Tacrolimus (reduced tacrolimus);Tacrolimus (tacrolimus elimination);Tacrolimus (tacrolimus control);Everolimus (reduced tacrolimus);Everolimus (tacrolimus elimination);Corticosteroids
27 Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients Completed NCT01150097 Phase 3 Tacrolimus (reduced tacrolimus);Everolimus (reduced tacrolimus);Tacrolimus (tacrolimus elimination);Everolimus (tacrolimus elimination);Tacrolimus (tacrolimus control);Corticosteroids
28 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Completed NCT02550288 Phase 3 Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule
29 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Completed NCT02460159 Phase 3 EZ 10 mg/Atorva 20 mg FDC;EZ 10 mg/Atorva 10 mg FDC
30 A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832) Completed NCT02741245 Phase 3 Ezetimibe 10 mg;Rosuvastatin 2.5 mg;Placebo for Ezetimibe;Placebo for Rosuvastatin
31 A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients Completed NCT01625377 Phase 3 tacrolimus;everolimus;Basiliximab;Mycophenolic Acid;Corticosteroids
32 Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 2, Phase 3 Seladelpar 2 mg Capsule;Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
33 Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders Recruiting NCT02937012 Phase 3 Bezafibrate;Ursodeoxycholic Acid;Placebo (for Bezafibrate)
34 Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation Recruiting NCT02584283 Phase 3 Glutathione
35 A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma Recruiting NCT02539537 Phase 3 Gemcitabine;Folinic Acid;5-Fluoro-uracil;Oxaliplatin;Irinotecan;L-folinic
36 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
37 Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Active, not recruiting NCT01802073 Phase 3 Oral Vancomycin
38 Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Active, not recruiting NCT01473524 Phase 3 Obeticholic Acid (OCA);Placebo
39 Remaxol® in Malignant Mechanical Jaundice Active, not recruiting NCT03416062 Phase 3 Remaxol®;Ringer's Solution
40 Remaxol® in Mechanical Jaundice of Non-malignant Origin Active, not recruiting NCT03418935 Phase 3 Remaxol (succinate + methionine + inosine + nicotinamide);Ringer's Solution
41 Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
42 Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice Unknown status NCT01275768 Phase 1, Phase 2
43 PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
44 Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP Completed NCT02098486 Phase 2 Moxifloxacin;ceftriaxone
45 Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
46 Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Completed NCT02177136 Phase 2 OCA;Placebo
47 Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
48 Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
49 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
50 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine

Search NIH Clinical Center for Cholangitis

Cochrane evidence based reviews: cholangitis

Genetic Tests for Cholangitis

Genetic tests related to Cholangitis:

# Genetic test Affiliating Genes
1 Cholangitis 29

Anatomical Context for Cholangitis

MalaCards organs/tissues related to Cholangitis:

41
Liver, T Cells, Colon, Neutrophil, Testes, Thyroid, B Cells

Publications for Cholangitis

Articles related to Cholangitis:

(show top 50) (show all 1938)
# Title Authors Year
1
Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. ( 29380060 )
2018
2
Clinical guidelines for primary sclerosing cholangitis 2017. ( 29951926 )
2018
3
Mucinous cystic neoplasm of the liver with extrahepatic growth presenting with ascending cholangitis diagnosed by endoscopic ultrasound features: a case report. ( 29444709 )
2018
4
The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. ( 29435321 )
2018
5
Urgent endoscopic retrograde cholangiopancreatography is not superior to early ERCP in acute biliary pancreatitis with biliary obstruction without cholangitis. ( 29401491 )
2018
6
Improvement of primary biliary cholangitis (PBC) under treatment with sulfasalazine and abatacept. ( 29754140 )
2018
7
Rituximab therapy in rheumatoid arthritis and primary biliary cholangitis. ( 29338925 )
2018
8
Symptoms do not Correlate With Findings From Colonoscopy in Children with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. ( 29378308 )
2018
9
Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment. ( 29889683 )
2018
10
Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. ( 29862092 )
2018
11
Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis. ( 29922759 )
2018
12
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. ( 29377235 )
2018
13
Response to Re: Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. ( 29878697 )
2018
14
Primary Biliary Cholangitis and Autoimmune Hepatitis. ( 29751878 )
2018
15
Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. ( 29320524 )
2018
16
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
17
Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. ( 29090868 )
2018
18
Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial. ( 29790196 )
2018
19
Congestive Heart Failure as a Differential Diagnosis of Cholangitis. ( 29716822 )
2018
20
Lack of Correlation of Liver Tests With Fibrosis Stage at Diagnosis in Pediatric Primary Sclerosing Cholangitis. ( 29356767 )
2018
21
Outcomes Associated With Timing of ERCP in Acute Cholangitis Secondary to Choledocholithiasis. ( 29356786 )
2018
22
A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis? ( 29316057 )
2018
23
The role of MRI and ERCP in the evaluation of disease activity and severity in primary sclerosing cholangitis. ( 29901259 )
2018
24
Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer. ( 29969801 )
2018
25
Peribiliary Cysts presenting as Primary Sclerosing Cholangitis. ( 29432923 )
2018
26
Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. ( 29090866 )
2018
27
Cholangitis complicated by infection of a simple hepatic cyst. ( 29948816 )
2018
28
Re: Acute cholangitis: current concepts. ( 29392900 )
2018
29
Clinical applicability of Tokyo guidelines 2018/2013 in diagnosis and severity evaluation of acute cholangitis and determination of a new severity model. ( 29374984 )
2018
30
Progress in Primary Biliary Cholangitis. ( 29874531 )
2018
31
Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314130 )
2018
32
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Trasnplantation for Primary Sclerosing Cholangitis. ( 29361103 )
2018
33
Cholangitis secondary to afferent loop syndrome from a gastric stump adenocarcinoma. ( 29620408 )
2018
34
Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept. ( 29854373 )
2018
35
Differential diagnosis of cholangiocarcinoma and IgG4-related sclerosing cholangitis by fluorescence inA situ hybridization using transpapillary forceps biopsy specimens. ( 29532638 )
2018
36
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. ( 29874528 )
2018
37
Shorter Duration of Antibiotic Treatment for Acute Bacteraemic Cholangitis with Successful Biliary Drainage:A Retrospective Cohort Study. ( 29408612 )
2018
38
Endoscopic diagnosis and treatment of biliary obstruction due to acute cholangitis and acute pancreatitis secondary to Fasciola hepatica infection. ( 29350372 )
2018
39
Endoscopic management of primary sclerosing cholangitis. ( 29883229 )
2018
40
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. ( 29808485 )
2018
41
Percutaneous cholecystostomy for high-risk patients with acute cholangitis. ( 29742738 )
2018
42
Kindler syndrome in a patient with colitis and primary sclerosing cholangitis: coincidence or association? ( 29634879 )
2018
43
Successful treatment of<i>Providencia rettgeri</i>cholecystitis and neutrophilic cholangitis in a cat. ( 29399368 )
2018
44
NELFCD and CTSZ loci are associated with jaundice-stage progression in primary biliary cholangitis in the Japanese population. ( 29795304 )
2018
45
Tokyo Guidelines 2018: updated Tokyo Guidelines for the management of acute cholangitis/acute cholecystitis. ( 29334699 )
2018
46
Increased Risk for Hip Fractures among Patients with Cholangitis: A Nationwide Population-Based Study. ( 29967788 )
2018
47
Localized intrahepatic IgG4-related sclerosing cholangitis (IgG4-SC) as an additional type of IgG4-SC: a systematic analysis of 12 cases. ( 29313399 )
2018
48
Diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. ( 29781738 )
2018
49
Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. ( 29977030 )
2018
50
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. ( 29851098 )
2018

Variations for Cholangitis

Expression for Cholangitis

Search GEO for disease gene expression data for Cholangitis.

Pathways for Cholangitis

GO Terms for Cholangitis

Cellular components related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 ALB CA2 CD40LG CRP F2 GGT1
2 extracellular exosome GO:0070062 9.4 ABCB4 ALB CA2 CEACAM5 CFTR CRP

Biological processes related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.72 CD40LG HLA-B HLA-DRB1 IL6 TNF
2 interferon-gamma-mediated signaling pathway GO:0060333 9.43 HLA-B HLA-DRB1 SP100
3 response to dexamethasone GO:0071548 9.37 ABCB4 CLDN1
4 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
5 acute-phase response GO:0006953 9.13 CRP F2 IL6
6 negative regulation of lipid storage GO:0010888 8.8 CRP IL6 TNF

Sources for Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....